

Resource Summary Report

Generated by ASWG on Aug 2, 2026

Experimental Pharmacology and Oncology Berlin-Buch

RRID:SCR_003954

Type: Tool

Proper Citation

Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954)

Resource Information

URL: <http://www.epo-berlin.com/>

Proper Citation: Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954)

Description: A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth.

Abbreviations: EPO

Synonyms: EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH

Resource Type: commercial organization

Keywords: tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target

Related Condition: Tumor, Cancer

Resource Name: Experimental Pharmacology and Oncology Berlin-Buch

Resource ID: SCR_003954

Alternate IDs: nlx_158355

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260801T190228+0000

Ratings and Alerts

No rating or validation information has been found for Experimental Pharmacology and Oncology Berlin-Buch.

No alerts have been found for Experimental Pharmacology and Oncology Berlin-Buch.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Sch??tte M, et al. (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature communications, 8, 14262.

Bradford JR, et al. (2016) Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget, 7(15), 20773.